IL-31 is a novel cytokine expressed in many human tissues and involved mainly in T H 2-weighted inflammation. IL-31 signals through a receptor complex consisting of IL-31 receptor a and oncostatin M receptor b. The available data show that IL-31 is strongly linked with chronic pruritic skin disorders, such as atopic eczema, and represents a novel target for directed drug therapy. Regulation of immune responses and cellular differentiation and proliferation are recently elucidated effects of IL-31, suggesting a more complex and diverse area of effect for this novel cytokine. This review summarizes the current knowledge on IL-31 and its receptors and the involvement of IL-31 in diseases both in human subjects and mouse models. (J Allergy Clin Immunol 2018;141:858-66.) 
IL-31, a novel cytokine, has been defined initially as a ''pruritogenic cytokine'' because of its increased tissue and serum levels in patients with pruritic and allergic diseases and a potential link between the immune and neuronal systems in inducing pruritus. [1] [2] [3] However, recent reports indicate a broader list of dermatologic and nondermatologic diseases displaying enhanced IL-31 expression and related proinflammatory and immunomodulatory functions, with effects reaching far beyond the induction of itch.
IL-31 is involved mainly in T H 2-weighted inflammation through release of various proinflammatory mediators. After binding to IL-31 receptor (IL-31R) complex, it plays a predominant function in mediation of inflammatory itch. Thus inhibition of IL-31 signaling might provide an effective treatment option for chronic pruritic skin diseases, such as atopic eczema (AE; atopic dermatitis). Additionally, maintenance of ongoing inflammation, modulation of immune response, and cell differentiation are recently elucidated effects of IL-31, which might fill in the gaps in the pathophysiology of inflammation. In this review we summarize current knowledge regarding IL-31 and IL-31R, their link with pruritic and nonpruritic diseases, and novel treatment options targeting the IL-31 pathway.
IL-31
IL-31 was discovered in 2004 by Dillon et al 4 as a 4-helix bundle cytokine belonging to the glycoprotein 130 (gp130)/IL-6 cytokine family. Other members of the IL-6 family are leukemia inhibitory factor, oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor, cardiotrophin-like cytokine, IL-6, and IL-11. Members of this family share the common chain of gp130 in their multiunit receptor and are involved in neuronal growth, bone metabolism, cardiac development, and immune regulation, such as T-cell differention. 5, 6 In contrast to the other members of this family, IL-31 does not use the common gp130 chain; instead, it uses IL-31 receptor a (IL-31RA).
The gene encoding human IL-31 is located on chromosome 12q24.31, and IL-31 cDNA is composed of an open reading frame encoding a 164-amino-acid precursor and a predicted 141-amino-acid mature polypeptide containing the 4 a-helix structure. 4 ,5 IL-31 is suggested to belong to the short-chain cytokine group, although it has 2 long and 2 short helices. 5 Initially, high levels of IL-31 have been demonstrated in patients with the pruritic skin disorder AE, with higher expression by activated CD4
1 T H 2 cells 4 and by skin-homing CD45RO 1 (memory) cutaneous lymphocyte-associated antigen-positive T cells. 7 However, lower levels of IL-31 expression have been also reported in T H 1 cells. 4 Other cell sources of IL-31 are CD8
1 T cells, monocytes/macrophages, dendritic cells, keratinocytes, eosinophils, basophils, mast cells, and fibroblasts. [8] [9] [10] Apart from the skin, IL31 mRNA was also found IL-31 production from cell sources seems to be dependent on IL-4, 11 which plays an important role in T H 2 polarization from naive T cells and in maintenance of T H 2 activation.
12 IL-33, a potent inducer of T H 2-associated cytokines, synergizes with IL-4 in the induction of IL-31 secretion. 13 Both physical and bacterial stress, such as UVB rays, H 2 O 2 , and staphylococcal enterotoxin B, as well as antimicrobial peptides, increase IL-31 expression. 1, 14 IL-31R COMPLEX IL-31RA mediates IL-31 signaling when coupled with oncostatin M receptor b (OSMRb) to form a functional receptor complex. 4 This receptor complex is expressed by a variety of epithelial and immune cells, including keratinocytes, mast cells, macrophages, eosinophils, basophils, a subset of peripheral neurons, and dorsal root ganglia. 2, 8, 9, 15 Immunoprecipitation experiments suggest that IL-31 binds predominantly to IL-31RA, but not to OSMRb, in the IL-31R complex. However, on coupling, OSMRb converts IL-31R into the high-affinity receptor and increases IL-31 binding. 16 IL-31RA belongs to the gp130 subfamily of type I cytokine receptors. It displays 28% homology to the common receptor component gp130 but lacks the IgG-like domain at the N-terminus. 4, 17 The human IL31RA gene is located on 5q11.2 in tandem with the gp130 gene, displaying an opposite transcriptional orientation. 17, 18 Before its ligand, IL-31, was identified, IL-31RA was named gp130-like monocyte receptor (GLM-R) 17 and glycoprotein 130-like receptor (GPL). 18 Several isoforms of IL-31RA have been described thus far (GPL560, GPL610, GPL626, GPL745, CRL3, and IL-31RAv1-v4) 5 ; however, their exact function and tissue distribution remain unclear. The short isoform (GPL560) has been shown to have an antagonizing 16 or lower activity compared with that of the long isoform (GPL745), 3 which might suggest a negative or neutralizing effect of some IL-31RA isoforms.
IL-31RA contains a cytokine-binding domain with 4 conserved cysteines, a WSDWS motif, and a region consisting of 3 fibronectin type III domain repeats. The intracellular part of the longer isoform contains a proline-rich region defining the box1 motif implicated in interaction with Janus kinases (Jaks). 16 Constitutive expression of human and mouse IL31RA mRNA can be detected in skin, brain, lung, trachea, skeletal muscle, testis, ovary, prostate, placenta, spleen, thymus, bone marrow, and blood leukocytes. 18 OSMRb not only is a subunit of IL-31R but also couples with gp130 to form type II receptor complex-binding OSM. Its dysregulated expression has been shown in different cancer types, such as cervical squamous cell carcinoma, breast cancer, and malignant melanoma. 19 In addition, mutations in the OSMR and IL31RA genes have been found to be associated with familial primary localized cutaneous amyloidosis (PLCA). 20, 21 The intracellular membrane-proximal region of OSMRb contains the proline-rich box1 region (CYPDIPDP), which recruits Jak1 and Jak2. OSMRb is expressed particularly in the vascular system, heart, lung, adipose tissue, skin, bladder, mammary tissue, adrenal gland, and prostate. 19 Three variants of OSMRb have been defined thus far, with varying expression patterns in different cancer types. 19, 22, 23 IFN-g and lipopolysaccharide (LPS) together induce expression of both receptor chains of IL-31R in human monocytes. 4 Interaction of the IL-31R complex with IL-31 results in activation of the Jak/signal transducer and activator of transcription (STAT) and phosphoinositide 3-kinase (PI3K)/AKT signal-transducing pathways and also activates different mitogen-activated protein kinase pathways, such as extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (Fig 1) . [24] [25] [26] Among subunits of IL-31R, OSMRb seems to be the major subunit in activation of the 3 pathways and signal transmission.
Once activated, Jaks are known to stimulate phosphorylation of the downstream signaling molecules STAT3, STAT5, and, to a lesser degree, STAT1. Tyrosine motifs as recruitment sites for STAT3 and STAT5 have been identified in both IL-31RA and OSMRb receptor subunits. 19 In addition, activation of STAT1, STAT3, and STAT5 was shown in transfectants expressing IL-31RA and OSMRb, but cell lines and primary cells expressing native receptors signaled mainly through STAT3. 4 However, cells lacking OSMRb have been shown to be unresponsive to IL-31.
27
Src homology domain 2-containing protein tyrosine phosphatase 2 and the adapter protein Shc, which have been shown to be involved in mitogen-activated protein kinase activation, can be recruited by OSMRb but not by IL-31RA. 28, 29 Consistently, IL-31-IL-31RA interaction alone was unable to activate ERK1/2 phosphorylation 28 ; however, MAPK cascade through IL-31 stimulation could be activated in a glioblastoma cell line expressing both IL-31RA and OSMRb. 16 Interaction of IL-31 and the IL-31RA/OSMRb receptor complex induces a slight but significant increase in phosphorylation of PI3K but a marked increase in phosphorylation of AKT. 16 Recruitment of Src homology domain 2-containing protein tyrosine phosphatase 2 has also been reported in PI3K phosphorylation; therefore activation of the PI3K/AKT pathway might rely exclusively on OSMRb. 30 
IL-31 AND PRURITUS: A LINK BETWEEN THE IMMUNE AND NEURAL SYSTEMS?
Although the exact mechanisms underlying pruritus are not fully understood, there are abundant data indicating cross-talk between the immune and neural system in induction of pruritus through activation of cytokine receptors on peripheral nerves. Tissue distribution analysis of IL-31R revealed that IL-31RA is most abundantly expressed in dorsal root ganglia, where cell bodies of cutaneous sensory neurons are located. 1 OSMRb expression was demonstrated in a subset of small-sized nociceptive neurons in the dorsal root ganglia, all of which also colocalized with IL-31RA, which project to the inner portion of lamina II in the dorsal horn of the spinal cord and the dermis of the skin. 15, 31 Not only cutaneous but also intrathecal injections of IL-31 evoked intense itch and induced atopic-like dermatitis in murine skin. 3 Evidence was also provided that functional IL-31RA is expressed by a small subpopulation of IL-31RA 
/TRPA1
1 neurons, suggesting that IL-31RA-mediated itch is linked to TRP channels. 3 In cultured primary sensory neurons, Ca 21 release and ERK1/2 phosphorylation were triggered by IL-31, and blockage of ERK1/2 with a specific inhibitor reduced scratching behavior in vivo, suggesting that ERK1/2 is involved in IL-31-induced itch transmission. 3 A recent study revealed elongation and branching of cutaneous nerve fibers in Il31-transgenic and IL-31 pumpequipped mice. The same effect was observed in smalldiameter neurons after treatment of isolated dorsal root ganglion neurons with IL-31 in vitro. 32 These data indicate that IL-31 might communicate directly with sensory nerves through activation of its high-affinity receptor complex and serve as a critical neuroimmune link between T H 2 cells and sensory neurons for the generation of T cell-mediated inflammatory itch.
Immunohistochemistry studies have shown epidermal expression of IL-31RA and OSMRb, 33, 34 which makes keratinocytes another important target of IL-31. Keratinocytes are known to produce itch-and pain-related mediators, which can initiate or maintain inflammatory reactions and directly interfere with sensory neurons. Toll-like receptor 2 ligand (Pam3Cys)-or IFN-g-induced upregulation of both IL-31RA and OSMRb and subsequent keratinocyte activation have been shown in human primary keratinocytes. Additionally, enhanced secretion of CCL2 from keratinocytes was observed after activation with IL-31. 35 Therefore an additional indirect role of IL-31 in pruritus through activating IL-31R on keratinocytes, which leads to subsequent release of pruritus-inducing mediators, also comes into question.
In addition to dorsal root ganglia and keratinocytes, eosinophils, 36 mast cells, 37 and basophils 9 are other pruritusassociated cellular targets of IL-31. A recent study showed greater release of IL-31 by eosinophils compared with IL-31 release by CD4 1 T cells, which could be further increased by T H 2 cytokines.
10 IL-31 could significantly induce chemotaxis, Ca 21 mobilization, and release of the proinflammatory cytokines IL-1b, IL-6, CXCL1, CXCL8, CCL2, CCL18, and CCL26 from eosinophils, which was further enhanced by coculture with keratinocytes but not with fibroblasts. 10, 36 This finding suggests an interaction between keratinocytes and eosinophils through IL-31 and might have particular importance in patients with pruritic skin disorders, such as AE, displaying an eosinophilic infiltration of lesional skin.
Mast cells play an important role in the induction of pruritus and allergic reactions through mediators, such as histamine or tryptase, which can directly modulate sensory nerves. 38 Mast cells have also been shown to be a source of IL-31. 39 The skin-derived antimicrobial peptides human b-defensins and LL-37 enhanced IL-31 gene expression and IL-31 production and release in a human mast cell line and in peripheral blood-derived cultured mast cells. However, concentrations of IL-31 produced by human b-defensins and LL-37 were low compared with the doses of IL-31 needed to exert its stimulatory functions. 39 Recently, basophils have been shown to be a strong source of IL-31. Stimulation of isolated basophils and CD4 1 T cells from the same healthy donors resulted in a significantly greater release of IL-31 from basophils than from CD4 1 T cells. 9 Additionally, IL-31 induced chemotaxis of basophils and secretion of IL-4 and IL-13 from these cells. 9 These results suggest an orchestrating role of IL-31 on other inflammatory cells related to pruritus and proinflammatory effects through release of other inflammatory mediators. Thus IL-31 has been shown to have direct or indirect connections with several pathways related to pruritus; however, further studies are required to enlighten the exact role of IL-31 in patients with pruritic disorders.
Animal models of IL-31 and pruritus
The ability of IL-31 to induce pruritus has been demonstrated in various species. Severe pruritus, alopecia, and skin lesions similar to human AE developed in either Il31-transgenic mice or wild-type mice after recombinant mouse IL-31 administration. 4 Skin lesions, which developed because of excessive scratching behavior, displayed similar histopathologic features as those in patients with AE. 4 In an AE-like murine model, intradermal IL-31 injection caused a gradual increase in long-lasting scratching about 3 hours after administration, followed by a gradual decrease lasting for more than 24 hours. 40 Il31 mRNA expression was associated with scratching behavior in the same murine model, 41 which was reduced by anti-IL-31 antibody. 42 IL-31RA-deficient mice showed a lower T H 2 immune response after nasal allergen administration but a stronger response after intraperitoneal administration. 43 Variation of immune responses in different tissues of IL-31RA-deficient mice might be related to distribution of different IL-31RA isotypes or varied compensatory activity of OSMRb in different tissues.
Systemically or locally (intravenous, subcutaneous, or intradermal) injected canine IL-31 rapidly induced pruritic behavior in the majority of dogs tested, and endogenous canine IL-31 was detected in the serum of dogs with AE but not in that of healthy control dogs. 44 Recently, the anti-canine IL-31 mAb lokivetmab was licensed by the US Department of Agriculture for the treatment of canine AE. Similarly, administration of recombinant cynomolgus IL-31 elicited an immediate scratching response in cynomolgus monkeys, which was inhibited by humanized anti-human IL-31 mAb administration in a dose-dependent manner. 45 Pathogenetic role of IL-31 in human chronic inflammatory skin diseases
The most prominent effect of IL-31 in inflammatory skin disorders is induction of pruritus. A human study investigating skin prick testing with IL-31 in healthy volunteers and patients with AE revealed no immediate but a late itch response. No significant difference in the initiation time, duration, and intensity of pruritus was observed between healthy control subjects and patients with AE. 46 This late response is similar to that seen in murine models; however, it differs from immediate pruritus in dogs and monkeys. An explanation suggested by the authors of this study 46 is the possible dominant indirect pruritic effect of IL-31 through keratinocytes and secondary inflammatory mediators in human subjects and mice as opposed to a direct effect in dogs and monkeys.
Other than induction of pruritus, the effects of IL-31 on keratinocyte differentiation and release of other proinflammatory cytokines might be involved in the pathogenesis of chronic inflammatory skin. Treatment of organotypic 3-dimensional skin models with IL-31 caused a disturbed keratinocyte differentiation caused by altered expression of genes encoding structural proteins, such as desmoglein, desmocollin, and filaggrin, and a subsequent increase in allergen and irritant penetration. 47 Moreover, IL-31 stimulated the expression of many genes encoding components of the IL-1 signaling network and increased the release of IL-1a, 47 enhanced expression of which causes hyperkeratosis and an inflammatory skin phenotype. 48, 49 Also, low doses of IL-31 stimulated expression of antimicrobial peptides, probably with the cooperation of IL-1 signaling, which could be inhibited by the IL-1R antagonist anakinra. 47 In addition to IL-1, IL-31 has been shown to stimulate the secretion of several other proinflammatory cytokines, such as IL-4, IL-6, IL-8, IL-13, IL-16, and IL-32; chemokines; and matrix metalloproteinases (MMPs) from other tissues, 9,50 suggesting a proinflammatory role of IL-31 also in chronic skin inflammation.
IL-31 and pruritic skin disorders
AE is a chronic inflammatory skin disease associated with intense pruritus. There is emerging evidence that IL-31 can play a role in the mechanism underlying pruritus in patients with AE. IL31 mRNA expression was increased in skin biopsy specimens of patients with AE compared with normal skin and correlated with IL4 and IL13 mRNA expression. 51 Atopy patch testing with staphylococcal enterotoxin B, which is frequently found in the skin of patients with AE, induced a rapid IL-31 expression in atopic subjects. 1 Patients with AE have higher levels of CD45RO 1 cutaneous lymphocyte-associated antigen-positive T cells that produce IL-31.
7 IL-31 serum levels are greater in adult and pediatric patients with AE compared with those in nonatopic healthy control subjects 52, 53 and correlate with disease activity. [53] [54] [55] Furthermore, T H 2-polarized T cells costimulated with antigen and staphylococcus enterotoxin B produce high levels of IL-31. 56 Previous results showed that repeated delivery of IL-31 is required to induce pruritus in mouse models. 44, 57 The frequent presence of bacterial products, such as staphylococcus enterotoxin B, on the skin of patients with AE might continuously increase IL-31 levels or lead to surpassing a threshold, which is required to initiate the itching behavior.
In the acute phase AE lesions are dominated by T H 2 cytokines, whereas chronic-phase AE lesions contain both T H 1-and T H 2-derived cytokines. 58, 59 Although IL-31 can be expressed by T H 1 cells, T H 2 cells seem to be a stronger source for IL-31 production. Thus the relationship between IL-31 and T H 1-weighted inflammation is less clear. Immunohistochemistry evaluation of several T H 1-and T H 2-weighted pruritic skin diseases found the highest expression of IL-31 in skin samples of patients with AE. 33 However, IL31 mRNA expression and immunoreactivity were not increased in T H 1-weighted nonpruritic psoriasis vulgaris or in pruritic psoriasis inversa. 33, 51 These data suggest that IL-31 can be functionally related to pruritus in patients with AE but is not a distinct feature of all pruritic skin disorders.
In addition to AE, IL-31 levels in human skin samples revealed increased expression of IL31 mRNA in prurigo nodularis and allergic contact dermatitis. 1, 51 Prurigo nodularis, one of the most pruritic skin disorders, showed the highest IL-31 expression at the mRNA level 1 but a lower expression compared with that seen in patients with AE at the protein level. 33 Recent reports revealed the genetic aspect of the link between IL-31 and eczematous diseases and demonstrated that the IL31 gene polymorphism is associated with increased risk of atopic and nonatopic eczema. [58] [59] [60] [61] [62] After these findings, several groups investigated the possible relation of IL-31 with other pruritic skin disorders (Fig 2 and Table I ). In patients with cutaneous T-cell lymphoma (CTCL), the malignant T-cell population has been shown to produce IL-31. 63 IL-31 and IL-31R expression was increased in skin samples of patients with CTCL. 34 In addition, increased serum levels of IL-31 that correlated with disease severity 64 and pruritus have been detected in patients with CTCL. 34, 63 The most common types of CTCL, mycosis fungoides and S ezary syndrome, are characterized by a T H 2-type cytokine profile, 65 which supports the T H 2-weighted proinflammatory role of IL-31, leading to induction of pruritus, with immunomodulatory effects contributing to disease progression.
Increased tissue expression of IL-31RA and OSMRb has been shown in skin specimens of patients with PLCA. However, cutaneous and serum IL-31 levels were not significantly higher in patients. 66 Although it is a highly pruritic skin disorder, IL-31 seems not to be directly associated with pruritus in patients with PLCA. Previous reports demonstrated an association between familial PLCA and mutations in OSMR and IL31RA genes. 20, 21 Therefore targeting IL-31R might be a therapeutic option in resistant cases.
Increased serum levels of IL-31 have been detected in patients with mastocytosis, 67, 68 with a positive correlation between serum levels and disease severity, tryptase levels, 67 and pruritus. 68 Moreover, distinct polymorphic variants of the IL31 gene have been shown to be more common in patients with mastocytosis compared with control subjects. 68 Interestingly, increased serum levels of IL-31 were higher in KIT D816V-positive adult patients, suggesting not only the role of IL-31 in the induction of pruritus in mastocytosis but also a possible pathophysiologic association with KIT mutation-dependent manifestations of the disease. 68 In patients with chronic spontaneous urticaria, serum levels of IL-31 have been found to be greater than in healthy control subjects but lower than in patients with AE. 69 Interestingly, basophils have been shown to be the predominant cells expressing IL-31 in skin lesions of patients with chronic spontaneous urticaria. 9 After treatment with omalizumab, a decrease in serum levels of IL-31 occurred; however, no correlation between IL-31 levels and urticaria severity was observed. 70 Most recently, serum levels and tissue expression of IL-31 have been found to be increased in patients with bullous pemphigoid and dermatitis herpetiformis. 71 Immunohistochemistry examination of lesional and perilesional skin specimens revealed a greater number of IL-31 1 cells in lesional specimens. Thus the authors suggested a contribution of IL-31 to blister formation in pruritic autoimmune blistering diseases. 71 
IL-31 in patients with nondermatologic diseases
Allergic asthma and rhinitis. Allergic asthma and rhinitis are characterized by aberrant T H 2 activation and constitute the atopic triad along with AE. Increased IL-31 protein and mRNA levels have been shown both in patients with allergic asthma and those with rhinitis (Table I) . [72] [73] [74] IL-31 single nucleotide polymorphisms were significantly correlated with serum IgE levels in asthmatic patients. 75 Among patients with asthma/rhinitis with positive specific IgE levels, patients with dust mite and mugwort allergy had higher IL-31 levels. 72 Increased local secretion of T H 2 cytokines and mucin production have been reported in patients with allergic rhinitis after induction with IL-31. 74 Therefore the IL-31 pathway might be a potential target in the treatment of allergic asthma and rhinitis.
Inflammatory bowel diseases. The IL-31R complex is expressed in the intestinal mucosa. 76 IL-31 induced secretion of chemokines (CXCL8 [IL-8), CXCL1, CCL7, CXCL3, CCL13, and CCL15), proinflammatory cytokines (IL-6, IL-16 and IL-32), and MMPs (MMP-1, MMP-3, MMP-25 and MMP-7) from colonic subepithelial myofibroblasts. 50 Increased migration and diverse modulation of cell proliferation depending on cell density (predominant antiproliferative effect) was observed in IL-31-induced intestinal epithelial cells. 76 In addition, IL31 mRNA expression was increased in the inflamed lesions of patients with Crohn disease and ulcerative colitis. 76 Taken together, IL-31 might play a role in inflammatory bowel diseases by promoting proinflammatory gene expression and modulating intestinal barrier function. Interestingly, an anti-inflammatory effect of IL-31 on T H 2 inflammation has also been reported after intestinal Trichuris muris infection, 77 which is contradictory to the proposed proinflammatory role of IL-31. Because the distribution of IL-31R isotypes in the mouse model is not mentioned in the latter study, 77 this result might be related to the enhanced expression of antagonizing IL-31RA subtypes in mouse intestines. However, further studies are required to elucidate the exact role of IL-31 in patients with intestinal diseases.
Malignancies. Although gain and loss of OSMRb expression have been related to different cancer entities, 19 there is limited evidence for the association of IL-31 with malignancies. Increased serum levels of IL-31 have been reported in several hematologic and solid tumours, 64, 67, 78, 79 but the in vitro studies have demonstrated antiproliferative activity of IL-31 in lung and intestinal cell lines. 25, 76 Murine colon carcinoma cells depleted of IL-31 exhibited increased invasive and migratory properties in vitro and faster tumor growth in vivo, which were both reversed by exogenous IL-31. 80 Compatibly, IL-31 was effective in suppressing proliferation by altering expression of cell-cycle proteins, including upregulation of p27(Kip1) and downregulation of cyclin B1, CDC2, CDK6, MCM4, and retinoblastoma through activation of STAT3. 25 IL-31 infusion reduced the number of metastatic lesions in the lungs of mice with metastatic breast carcinoma, and combination of chemotherapy with a long-lived IL-31-IgG fusion protein reduced tumor growth, angiogenesis, and pulmonary metastasis to a greater extent than when chemotherapy was used alone. 80 Additionally, serum IL-31 levels were negatively correlated with the progression of human non-small cell lung cancer. 81 These findings indicate a possible future role of IL-31 in the treatment of malignancies.
Osteoporosis. Serum levels of IL-31 have been shown to be higher in postmenopausal osteoporotic female patients compared with healthy postmenopausal control subjects. However, the difference was statistically significant only in older subjects (age >65 years), and no significant correlation between the severity of osteoporosis and IL-31 levels has been found. 82 Similar to the effects of IL-31 on keratinocyte differentiation through destruction of structural proteins, these results indicate that IL-31 can participate in the inflammatory process in various tissues either as a proinflammatory or an immunomodulatory cytokine and lead both to tissue destruction and ''inflammaging.''
THERAPEUTIC APPROACHES
The first human study investigating the blockade of IL-31 signaling was performed with nemolizumab (CIM331), a humanized anti-human IL-31RA mAb, in healthy subjects and patients with AE. 83 Single subcutaneous administration of nemolizumab significantly reduced visual analogue scale (VAS) scores for pruritus and the use of topical steroids. In parallel with the decrease in pruritus, an increase in sleep efficiency was observed. Exacerbation of AE and folliculitis were the most common adverse events in patients with AE receiving nemolizumab or placebo. Increased creatine phosphokinase and hepatic enzyme activity (aspartate transaminase and alanine transaminase) was more common in healthy control subjects receiving nemolizumab than in control subjects receiving placebo, which might be related to exercise or concomitant medication. 83 A phase 2 trial compared the effects of subcutaneous nemolizumab (0.1, 0.5, or 2.0 mg/kg) and placebo administration every 4 weeks in patients with AE. At week 12, VAS scores for pruritus, Eczema Area Severity Index scores, SCORAD scores, and body surface area of AE involvement were decreased, whereas several parameters assessing sleep quality and the Dermatology Quality of Life Index improved in the nemolizumab group compared with the placebo group, with a dose of 0.5 mg/kg every 4 weeks showing the best benefit/risk profile. 84 Regarding adverse events, exacerbation of AE and peripheral edema occurred more frequently in patients receiving nemolizumab than placebo. 84 Fifty-two-week extension of a phase 2 study assessing long-term efficacy and safety of nemolizumab showed up to 80% improvement in VAS and Eczema Area Severity Index scores, which shows breakage of the itch-scratch cycle and inhibition of IL-31-related proinflammatory environment led to a pronounced improvement in the severity of AE. 85 Blockade of IL-31 through the caninized, anti-canine IL-31 mAb lokivetmab (ZTS-00103289) has been shown to reduce pruritus and skin lesions in dogs with AE. 86 No serious adverse events and drug interactions between lokivetmab and other concomitantly administered medications were observed in a recent study assessing the safety profile of lokimetvab. 87 Thus in addition to the highly effective blockade of the IL-31 pathway with IL-31RA mAb in patients with AE, a humanized anti-human IL-31 mAb (BMS-981164) might be another alternative for these patients; however, no current information about the phase 1 study of single-dose BMS-981164 administration in patients with AE and healthy subjects is available thus far.
CONCLUSIONS AND OUTLOOK
Since the first description of IL-31 in 2004, numerous studies led to a general understanding about the biology of this novel cytokine. The generation of mAbs targeting the IL-31 pathway poses an exciting development in the era of pruritic skin diseases. However, current knowledge shows that the effects of IL-31 are not limited to the induction of pruritus but that it has a broad spectrum of action as a proinflammatory and immunomodulatory cytokine; thus it fills one of the gaps between healthy and inflamed tissue. Future studies are required to understand the exact mechanism of IL-31, to elucidate further indications of inhibiting its pathway, and to define the role of IL-31-targeted interventions in the management of chronic inflammatory diseases.
